<?xml version="1.0" encoding="UTF-8"?>
<p>There is no cure for HSV-1 or HSV-2, but antiviral medications are commonly used to prevent, shorten, or reduce severity of recurrent outbreaks.
 <sup>
  <xref rid="bibr6-2515690X20978394" ref-type="bibr">6</xref>
 </sup> Acyclic guanosine analogues that target viral DNA replication are the first-line therapy in the management of HSV.
 <sup>
  <xref rid="bibr12-2515690X20978394" ref-type="bibr">12</xref>
 </sup> Of this class, acyclovir has been considered the gold standard for both prophylaxis and treatment since the 1980s.
 <sup>
  <xref rid="bibr12-2515690X20978394" ref-type="bibr">12</xref>
 </sup> However, the evidence for the use of acyclovir and other nucleoside analogues for both herpes labialis and herpes genitalis in this manner has produced inconsistent results.
 <sup>
  <xref rid="bibr13-2515690X20978394" ref-type="bibr">13</xref>
  <xref rid="bibr14-2515690X20978394" ref-type="bibr"/>
  <xref rid="bibr15-2515690X20978394" ref-type="bibr"/>â€“
  <xref rid="bibr16-2515690X20978394" ref-type="bibr">16</xref>
 </sup> Considering the chronic nature of HSV infections, long-term use of antiviral medications has led to cases of drug resistance, particularly in immunocompromised individuals.
 <sup>
  <xref rid="bibr12-2515690X20978394" ref-type="bibr">12</xref>
 </sup> This places an importance in exploring new and effective strategies and therapies to prevent and treat HSV outbreaks.
</p>
